A detailed history of Eversept Partners, LP transactions in Mannkind Corp stock. As of the latest transaction made, Eversept Partners, LP holds 2,256,952 shares of MNKD stock, worth $16 Million. This represents 0.89% of its overall portfolio holdings.

Number of Shares
2,256,952
Previous 2,391,128 5.61%
Holding current value
$16 Million
Previous $10.8 Million 8.77%
% of portfolio
0.89%
Previous 0.81%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$4.05 - $5.43 $543,412 - $728,575
-134,176 Reduced 5.61%
2,256,952 $11.8 Million
Q1 2024

May 15, 2024

BUY
$3.25 - $5.27 $7.77 Million - $12.6 Million
2,391,128 New
2,391,128 $10.8 Million
Q2 2021

Aug 16, 2021

SELL
$3.61 - $5.45 $7.82 Million - $11.8 Million
-2,165,383 Closed
0 $0
Q1 2021

Nov 08, 2023

BUY
$3.14 - $6.14 $6.8 Million - $13.3 Million
2,165,383 New
2,165,383 $8.49 Million
Q1 2021

May 13, 2021

BUY
$3.14 - $6.14 $6.8 Million - $13.3 Million
2,165,383 New
2,165,383 $8.49 Million

Others Institutions Holding MNKD

About MANNKIND CORP


  • Ticker MNKD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 257,338,000
  • Market Cap $1.82B
  • Description
  • MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocri...
More about MNKD
Track This Portfolio

Track Eversept Partners, LP Portfolio

Follow Eversept Partners, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eversept Partners, LP, based on Form 13F filings with the SEC.

News

Stay updated on Eversept Partners, LP with notifications on news.